New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in ...

Emerging research highlights the cardiovascular benefits of popular anti-obesity medications, such as GLP-1-based therapies.

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating ...

JACC is publishing two secondary analyses on ... in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Tirzepatide has already been FDA approved for weight loss.

JACC is publishing two secondary analyses on ... in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Tirzepatide has already been FDA approved for weight loss.

demonstrating that tirzepatide significantly lowered the risk of worsening heart failure events in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Additionally ...

Our focus is on HFrEF including familal, dilated cardiomyopathy, HFpEF including amyloid cardiomyopathy ... Journal of Cardiac Failure, JACC: Cardiovascular Interventions, ASAIO, and American Journal ...

We continue to be very enthusiastic about advancing TX45 as a potential best-in-class, long-acting relaxin therapeutic for patients with PH-HFpEF,” said Alise Reicin, M.D., President and Chief ...